Bright Minds Biosciences Files 6-K, Incorporates News Release
Ticker: DRUG · Form: 6-K · Filed: Nov 17, 2025 · CIK: 1827401
Sentiment: neutral
Topics: filing, news-release, registration-statement
Related Tickers: BMBS
TL;DR
BMBS filed a 6-K with a news release on Nov 17, 2025. Check F-3 filings.
AI Summary
Bright Minds Biosciences Inc. filed a Form 6-K on November 17, 2025, incorporating a news release dated November 17, 2025. This filing is related to their registration statements on Form F-3 (File No. 333-284694 and 333-289851). The company's principal executive office is located at 19 Vestry Street, New York, NY 10013.
Why It Matters
This filing indicates ongoing regulatory activity and incorporation of important company news into SEC filings, which is crucial for investors tracking the company's disclosures.
Risk Assessment
Risk Level: low — This is a routine filing of a news release and does not appear to contain significant new financial or operational information that would immediately alter risk.
Key Numbers
- 001-40997 — SEC File Number (Identifies the company's filing history with the SEC)
- 333-284694 — Registration Statement File Number (Related to prior F-3 filing)
- 333-289851 — Registration Statement File Number (Related to prior F-3 filing)
Key Players & Entities
- Bright Minds Biosciences Inc. (company) — Filer of the Form 6-K
- November 17, 2025 (date) — Filing date and news release date
- 19 Vestry Street, New York, NY 10013 (address) — Principal executive office
- Form F-3 (File No. 333-284694) (document) — Incorporated by reference
- Form F-3 (File No. 333-289851) (document) — Incorporated by reference
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report a news release dated November 17, 2025, and to incorporate it by reference into existing registration statements on Form F-3.
Which registration statements are being updated by this filing?
This filing incorporates Exhibit 99.1 into registration statements on Form F-3 with File Numbers 333-284694 and 333-289851.
Where is Bright Minds Biosciences Inc.'s principal executive office located?
The principal executive office is located at 19 Vestry Street, New York, NY 10013.
What type of report is this Form 6-K?
This is a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.
What is the SEC file number for Bright Minds Biosciences Inc.?
The SEC file number for Bright Minds Biosciences Inc. is 001-40997.
Filing Stats: 221 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2025-11-17 17:11:25
Filing Documents
- form6k.htm (6-K) — 5KB
- exhibit99-1.htm (EX-99.1) — 22KB
- exhibit99-1x001.jpg (GRAPHIC) — 4KB
- 0001062993-25-016913.txt ( ) — 33KB
From the Filing
Bright Minds Biosciences Inc.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F [ X ] Form 40-F [ ] INCORPORATION BY REFERENCE Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into our (a) registration statement on Form F-3 (File No. 333-284694), originally filed on February 5, 2025, and the prospectus thereto filed on February 14, 2025, and (b) registration statement on Form F-3 (File No. 333-289851), originally filed on August 25, 2025. SUBMITTED HEREWITH Exhibits 99.1 News Release dated November 17, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BRIGHT MINDS BIOSCIENCES INC. (signed) " Ryan Cheung " Ryan Cheung Chief Financial Officer Date: November 17, 2025